JP2021527039A5 - - Google Patents

Info

Publication number
JP2021527039A5
JP2021527039A5 JP2020567578A JP2020567578A JP2021527039A5 JP 2021527039 A5 JP2021527039 A5 JP 2021527039A5 JP 2020567578 A JP2020567578 A JP 2020567578A JP 2020567578 A JP2020567578 A JP 2020567578A JP 2021527039 A5 JP2021527039 A5 JP 2021527039A5
Authority
JP
Japan
Prior art keywords
patent document
document
application publication
prior
patent application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020567578A
Other languages
English (en)
Japanese (ja)
Other versions
JP7794564B2 (ja
JP2021527039A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/035576 external-priority patent/WO2019236703A1/en
Publication of JP2021527039A publication Critical patent/JP2021527039A/ja
Publication of JP2021527039A5 publication Critical patent/JP2021527039A5/ja
Priority to JP2024056596A priority Critical patent/JP2024096738A/ja
Application granted granted Critical
Publication of JP7794564B2 publication Critical patent/JP7794564B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020567578A 2018-06-05 2019-06-05 悪性リンパ腫性障害の治療法 Active JP7794564B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024056596A JP2024096738A (ja) 2018-06-05 2024-03-29 悪性リンパ腫性障害の治療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862680739P 2018-06-05 2018-06-05
US62/680,739 2018-06-05
PCT/US2019/035576 WO2019236703A1 (en) 2018-06-05 2019-06-05 Methods of treating malignant lymphoproliferative disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024056596A Division JP2024096738A (ja) 2018-06-05 2024-03-29 悪性リンパ腫性障害の治療法

Publications (3)

Publication Number Publication Date
JP2021527039A JP2021527039A (ja) 2021-10-11
JP2021527039A5 true JP2021527039A5 (https=) 2022-06-13
JP7794564B2 JP7794564B2 (ja) 2026-01-06

Family

ID=68769443

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020567578A Active JP7794564B2 (ja) 2018-06-05 2019-06-05 悪性リンパ腫性障害の治療法
JP2024056596A Pending JP2024096738A (ja) 2018-06-05 2024-03-29 悪性リンパ腫性障害の治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024056596A Pending JP2024096738A (ja) 2018-06-05 2024-03-29 悪性リンパ腫性障害の治療法

Country Status (11)

Country Link
US (3) US11510904B2 (https=)
EP (1) EP3801768A4 (https=)
JP (2) JP7794564B2 (https=)
KR (1) KR20210045364A (https=)
CN (2) CN112351819B (https=)
AU (1) AU2019280693B2 (https=)
BR (1) BR112020024931A2 (https=)
CA (1) CA3102555A1 (https=)
IL (2) IL315565A (https=)
MX (2) MX2020013163A (https=)
WO (1) WO2019236703A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801768A4 (en) * 2018-06-05 2022-04-20 Actuate Therapeutics Inc. METHODS OF TREATMENT OF LYMPHOPROLIFERATIVE MALIGNANT DISEASES
CN115697323A (zh) * 2019-12-26 2023-02-03 开动疗法公司 用于治疗骨髓纤维化的化合物
US20240009170A1 (en) * 2020-11-17 2024-01-11 Brown University Inhibition of glycogen synthase kinase-3 (gsk-3)
JP2022157223A (ja) * 2021-03-31 2022-10-14 国立大学法人神戸大学 抗ガン剤効果増強剤
CN113684180B (zh) * 2021-08-31 2023-05-26 山东大学第二医院 一种提高骨髓瘤杀伤活性的nk细胞制备方法
WO2023172629A2 (en) * 2022-03-08 2023-09-14 Brown University Anticancer maleimide derivatives for use with immune checkpoint blockade
JP2025525407A (ja) * 2022-06-27 2025-08-05 アクチュエイト セラピューティクス インク. エルラグルシブの経口剤形
EP4565217A1 (en) * 2022-08-04 2025-06-11 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of lymphoproliferative disorders
WO2025245059A1 (en) * 2024-05-23 2025-11-27 Yale University Compositions comprising gsk-3 and/or beta-catenin inhibitors and/or degraders and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2446269T3 (es) 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
AU2013224302B2 (en) * 2012-02-21 2017-03-30 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
US20160375006A1 (en) * 2012-10-12 2016-12-29 The Broad Institute, Inc. Uses of paralog-selective inhibitors of gsk3 kinases
RS58700B1 (sr) 2012-10-12 2019-06-28 Broad Inst Inc Gsk3 inhibitori i postupci njihove primene
WO2014165851A1 (en) * 2013-04-05 2014-10-09 The Children's Hospital Of Philadelphia Transient up-regulation of myc in b-cell lymphomas
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
JP6534098B2 (ja) * 2014-09-12 2019-06-26 国立大学法人 鹿児島大学 成人t細胞白血病治療薬
EP3801768A4 (en) * 2018-06-05 2022-04-20 Actuate Therapeutics Inc. METHODS OF TREATMENT OF LYMPHOPROLIFERATIVE MALIGNANT DISEASES

Similar Documents

Publication Publication Date Title
JP2021527039A5 (https=)
NO20080362L (no) CD19-antistoffer og deres anvendelser
Gao et al. Human endogenous retroviruses in cancer: Expression, regulation and function
MX374906B (es) Nuevos inmunoconjugados
NO20081987L (no) Humane, monoklonale antistoffer mot CD70
MX2024002353A (es) Celulas asesinas naturales modificadas geneticamente.
JP2019502892A5 (https=)
JP2014087372A5 (https=)
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
PH12022553257A1 (en) Antibodies to tigit
JP2021524958A5 (https=)
FI2884999T4 (fi) Menetelmä ja koostumuksia soluimmunoterapiaa varten
NO20073797L (no) Humane monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA)
Pei et al. Current progress in EBV-associated B-cell lymphomas
PH12018501291A1 (en) Group b adenovirus encoding an anti-tcr-complex antibody or fragment
MX354450B (es) Anticuerpos anti proteína accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos.
IN2014CN02518A (https=)
TW200730624A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
JP2014519854A5 (https=)
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
EA200602241A1 (ru) Замещённые индазолы, композиции, содержащие указанные индазолы, способ их получения и применение
MA35366B1 (fr) Procédés de traitement du cancer à l'aide d'antagonistes se liant à l'axe pd-1 et inhibiteurs de mek
TN2011000283A1 (en) Human cgrp receptor binding proteins
EA201790175A1 (ru) Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований
JP2018525453A5 (https=)